·6 min read·science
The next-gen GLP-1 horizon: orforglipron, CagriSema, MariTide, and which to actually wait for
Three drugs are about to change the GLP-1 conversation again. Orforglipron just got FDA approval. CagriSema is in phase 3 readouts. MariTide is the longer-tail bet. Here's the honest read on which deserves your patience and which is hype.